环孢素、度普利尤单抗与甲氨蝶呤治疗特应性皮炎的真实世界比较:UK-Irish A-STAR登记研究
该前瞻性观察性队列研究纳入488例成人和儿童特应性皮炎患者,比较环孢素、度普利尤单抗与甲氨蝶呤的真实世界疗效与安全性。度普利尤单抗和环孢素比甲氨蝶呤更快达到EASI-50/75/90,度普利尤单抗在EASI、POEM、PP-NRS和DLQI改善上优于甲氨蝶呤,环孢素在重症患者中改善更显著,三组不良事件发生率相似。
要点
- 度普利尤单抗和环孢素比甲氨蝶呤更快达到EASI-50/75/90。
- 度普利尤单抗在EASI、POEM、PP-NRS和DLQI改善上优于甲氨蝶呤。
- 环孢素在重症患者中EASI、POEM和PP-NRS改善更显著。
核心结论
- 度普利尤单抗疗效一致优于甲氨蝶呤,环孢素在1年随访内对极重度疾病最有效。
研究设计与样本
- 前瞻性观察性队列研究,纳入UK-Irish A-STAR登记中488例成人和儿童特应性皮炎患者(311例成人、177例儿童/青少年)。
- 度普利尤单抗282例、甲氨蝶呤149例、环孢素57例;治疗至少28天,随访12个月。
主要发现
- 度普利尤单抗和环孢素组比甲氨蝶呤组更快达到EASI-50、EASI-75和EASI-90。
- 校正既往严重度后,度普利尤单抗组EASI、POEM、PP-NRS和DLQI的下降大于甲氨蝶呤组。
- 重症患者中环孢素组EASI、POEM和PP-NRS下降更显著。
- 不良事件发生率三组相似:环孢素734、度普利尤单抗654、甲氨蝶呤594每10 000人月。
关键数值与推荐
- 疗效指标包括EASI、POEM、PP-NRS、DLQI和cDLQI。
- 采用校正Cox回归分析比较达到EASI-50/75/90的风险比,线性混合效应模型估计疗效评分变化。
临床怎么用
- 度普利尤单抗可作为优于甲氨蝶呤的系统治疗选择。
- 环孢素可用于极重度特应性皮炎患者的短期治疗。
- 三组安全性相似,选择需结合患者严重度和治疗线数。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The main conventional systemic treatments for atopic dermatitis (AD) are methotrexate (MTX) and ciclosporin (CyA). Dupilumab was the first novel systemic agent to enter routine clinical practice. There are no head-to-head randomized controlled trials or real-world studies comparing these agents directly. Network meta-analyses provide indirect comparative efficacy and safety data and have shown strong evidence for dupilumab and CyA. OBJECTIVES: To compare the real-world clinical effectiveness and safety of CyA, dupilumab and MTX in AD. METHODS: We compared the effectiveness and safety of these systemic agents in a prospective observational cohort study of adult and paediatric patients recruited into the UK-Irish Atopic eczema Systemic TherApy Register (A-STAR). Treatment effectiveness measures included Eczema Area and Severity Index (EASI), Patient-Oriented Eczema Measure (POEM), Peak Pruritus Numerical Rating Scale (PP-NRS), Dermatology Life Quality Index (DLQI) and children's DLQI (cDLQI). The minimum duration of treatment was 28 days and follow-up was 12 months. Adjusted Cox-regression analysis was used to compare the hazard ratios of achieving EASI-50, EASI-75 and EASI-90 over time, and linear mixed-effects models were used to estimate changes in efficacy scores. Treatment safety was assessed by examining adverse events (AEs) at follow-up visits. RESULTS: We included 488 patients (311 adults and 177 children/adolescents) on dupilumab (n = 282), MTX (n = 149) or CyA (n = 57). CyA and MTX were primarily used as the first-line treatment, while dupilumab was mainly a second-line systemic treatment as per UK National Institute of Clinical and Care Excellence (NICE) recommendations. EASI-50, EASI-75 and EASI-90 were achieved more rapidly in the dupilumab and CyA groups compared with MTX. After adjustment for previous severity, the reduction in EASI, POEM, PP-NRS and DLQI was greater for patients treated with dupilumab compared with MTX. In patients with severe disease the reduction in EASI, POEM and PP-NRS was even greater with CyA. The incidence rates of AEs were similar across groups (734, 654 and 594 per 10 000 person-month on CyA, dupilumab and MTX, respectively). CONCLUSIONS: This real-world comparison of CyA, dupilumab and MTX in AD suggests that dupilumab is consistently more effective than MTX and that CyA is most effective in very severe disease within 1 year of follow-up. Atopic dermatitis (AD) is a common skin disease which causes dry and itchy skin. AD affects around one in five children and one in 10 adults in the UK. The main conventional systemic treatments are with drugs called methotrexate (MTX) and ciclosporin (CyA). As well as these, dupilumab was the first novel systemic agent to enter routine clinical practice. However, there are no studies that have directly compared the effectiveness or safety of these treatments. This study aimed to compare the effectiveness and safety of CyA, dupilumab and MTX. We compared these treatments in adults and children with AD who were participating in the UK–Irish Atopic eczema Systemic TherApy Register (A-STAR). Treatment effectiveness was assessed using the Eczema Area and Severity Index (EASI), and with patient-reported severity scores for itch and quality of life. Patients were treated for a minimum of 28 days and followed up for 12 months. Treatment safety was determined by patient-reported side-effects at follow-up visits. A total of 488 patients were assessed, including 282 patients on dupilumab, 149 on MTX and 57 on CyA. We found that the time taken for AD severity EASI scores to reduce by 50%, 75% and 90% was shorter for patients on dupilumab and CyA, compared with MTX. Improvements in itch and quality of life were greater for patients treated with dupilumab, compared with MTX. In patients with severe AD, improvement was even greater than with CyA. The incidence of side-effects was similar with dupilumab, CyA and MTX treatments. Overall, our findings suggest that dupilumab is consistently more effective than MTX and that CyA is most effective in very severe disease within 1 year of follow-up.
引用
- Alexander H, Malek R, Prieto-Merino D, et al. A prospective observational cohort study comparing the treatment effectiveness and safety of ciclosporin, dupilumab and methotrexate in adult and paediatric patients with atopic dermatitis: results from the UK-Irish A-STAR register. Br J Dermatol. 2024. PMID: 39044673. doi:10.1093/bjd/ljae287
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。